What's Happening?
Peli BioThermal, a leader in temperature-controlled logistics solutions, has acquired Evo from BioLife Solutions to expand its product portfolio and enhance its capabilities in the Cell and Gene Therapy sector. The acquisition includes cryogenic shippers and the evoIS technology platform, which are crucial for the precise and reliable transport of life-saving therapies. This strategic move aims to provide a comprehensive range of cold chain solutions, offering greater choice and convenience to existing and new customers in the pharmaceutical and biopharmaceutical industries.
Why It's Important?
The acquisition of Evo by Peli BioThermal is significant for the Cell and Gene Therapy market, which demands high precision and reliability in logistics. By integrating Evo's products, Peli BioThermal can offer a full spectrum of temperature-controlled solutions, enhancing its service offerings and strengthening customer relationships. This expansion is poised to accelerate innovation and scale, providing better support for the growing needs of the life sciences industry. The move also reflects the increasing importance of cold chain logistics in ensuring the safe and effective delivery of advanced therapies.
What's Next?
Following the acquisition, Peli BioThermal plans to leverage its global resources to scale growth and innovation in the cold chain logistics sector. The integration of Evo's products will allow Peli BioThermal to deepen its engagement with existing customers and access new high-growth markets. The company is committed to investing in its capabilities to meet the evolving demands of the Cell and Gene Therapy industry, ensuring continuity of expertise and customer support through its expanded portfolio.
